Doxazosin GITS (Cardura XL)

PreclinicalSmall molecule

Doxazosin GITS (Cardura XL) is one of 11 small molecule programs targeting Urinary retention. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary RetentionActive, not recruiting

Urinary RetentionPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Urinary Retention

#DrugCompanyPhaseTrials

Flomax

Sanofi

Approved

16 2

Robinul

Avodart

1 4

Ivadantin

PProcter and Gamble

Approved

1 5

Esmeron

FFresenius Kabi USA, LLC

Tamsulosin OCAS

5 7

No Intrathecal Morphine

UUniversity of Toronto

Phase 3

1 8

Minipress

Pfizer

Preclinical

—9

Decadron

AAspen Global Incorporated

Preclinical

1 10

Hytrin

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Urinary retention1 trial

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Terminated·HHospital Authority, Hong Kong·N/A·NCT00563485·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Doxazosin GITS (Cardura XL). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxazosin GITS (Cardura XL) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxazosin GITS (Cardura XL). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Authority, Hong Kong company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHospital Authority, Hong Kong

Doxazosin GITS (Cardura XL)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Urinary retention1 trial

References

Drug Info

Quick Facts

Related News